U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H12Cl2F3N7O2S
Molecular Weight 506.289
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAK-580

SMILES

C[C@@H](NC(=O)C1=C(Cl)C(N)=NC=N1)C2=NC=C(S2)C(=O)NC3=NC=C(Cl)C(=C3)C(F)(F)F

InChI

InChIKey=VWMJHAFYPMOMGF-ZCFIWIBFSA-N
InChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)/t6-/m1/s1

HIDE SMILES / InChI

Molecular Formula C17H12Cl2F3N7O2S
Molecular Weight 506.289
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

BIIB-024, also known as MLN2480, and AMG 2112819, is an oral, selective pan-Raf kinase inhibitor. The Raf kinases (A-Raf, B-Raf and C-Raf) are key regulators of cell proliferation and survival within the mitogen-activated protein kinase (MAPK) pathway. The MAPK pathway is frequently disregulated in human cancers, often via activating mutations of Ras or Raf. BIIB-024 inhibits MAPK pathway signaling in BRAF mutant and some RAS mutant preclinical cancer models at concentrations that are tolerated in vivo. BIIB-024 is most potent in BRAF mutant melanoma models but also has single agent activity in some RAS mutant models. The combination of BIIB-024 with TAK-733 inhibits the growth of a broader range of RAS mutant tumor models than single agent BIIB-024, including primary human tumor xenograft models of melanoma and CRC. BIIB-024 is in phase I clinical trials for the treatment of malignant melanoma and solid tumours.

Approval Year

Patents

Sample Use Guides

In Vivo Use Guide
100 mg, tablets, orally, once on protocol specified days of a 28-day Cycle for up to 12 Cycles
Route of Administration: Oral
In Vitro Use Guide
BIIB-024 inhibits a small subset of kinases in a similar range as Raf kinases (IC50 1-50 nM)
Substance Class Chemical
Created
by admin
on Tue Oct 22 12:06:59 UTC 2019
Edited
by admin
on Tue Oct 22 12:06:59 UTC 2019
Record UNII
ZN90E4027M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TAK-580
Common Name English
BIIB024
Code English
TAK 580 [WHO-DD]
Common Name English
4-PYRIMIDINECARBOXAMIDE, 6-AMINO-5-CHLORO-N-((1R)-1-(5-(((5-CHLORO-4-(TRIFLUOROMETHYL)-2-PYRIDINYL)AMINO)CARBONYL)-2-THIAZOLYL)ETHYL)-
Systematic Name English
6-AMINO-5-CHLORO-N-((1R)-1-(5-(((5-CHLORO-4-(TRIFLUOROMETHYL)-2-PYRIDINYL)AMINO)CARBONYL)-2-THIAZOLYL)ETHYL)-4-PYRIMIDINECARBOXAMIDE
Systematic Name English
BIIB-024
Common Name English
MLN-2480
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 410813
Created by admin on Tue Oct 22 12:06:59 UTC 2019 , Edited by admin on Tue Oct 22 12:06:59 UTC 2019
Code System Code Type Description
ChEMBL
CHEMBL3348923
Created by admin on Tue Oct 22 12:06:59 UTC 2019 , Edited by admin on Tue Oct 22 12:06:59 UTC 2019
PRIMARY
PUBCHEM
25161177
Created by admin on Tue Oct 22 12:06:59 UTC 2019 , Edited by admin on Tue Oct 22 12:06:59 UTC 2019
PRIMARY
EPA CompTox
1096708-71-2
Created by admin on Tue Oct 22 12:06:59 UTC 2019 , Edited by admin on Tue Oct 22 12:06:59 UTC 2019
PRIMARY
CAS
1096708-71-2
Created by admin on Tue Oct 22 12:06:59 UTC 2019 , Edited by admin on Tue Oct 22 12:06:59 UTC 2019
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY